Jupiter Neurosciences, Inc. announced on February 3, 2025, an agreement with Catalent Pharma Solutions, LLC for the production of JOTROL™ softgel capsules. This manufacturing partnership is crucial for supporting the company's upcoming Phase 2a clinical trial in Parkinson’s disease.
Under the terms of the agreement, Catalent will be responsible for manufacturing JOTROL™ softgel capsules. This ensures a reliable supply of the proprietary resveratrol-based platform for clinical development.
This agreement represents a significant operational step forward, securing the necessary resources to advance JOTROL™ through its clinical development stages. It underscores the company's commitment to progressing its therapeutic pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.